Technical Scrutiny on Health Care Sector Stocks - ImmunoGen, Arrowhead Research, Chimerix, Tekmira Pharma, and Celgene

LONDON, October 15, 2014 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Arrowhead Research Corporation (NASDAQ: ARWR), Chimerix Inc. (NASDAQ: CMRX), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), and Celgene Corporation (NASDAQ: CELG). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, October 14, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 16,315.19, down 0.04% and the NASDAQ Composite closed at 4,227.17, up 0.32%. The S&P 500 finished the session 0.16% higher at 1,877.70. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 705.81, down 0.76%, whereas the index has advanced 9.89% on YTD basis. Register for your complimentary reports on these five stocks at:  

http://investor-edge.com/register

ImmunoGen Inc.'s stock fell 2.25%, to close the day at $8.67. The stock recorded a trading volume of 1.19 million shares, above its three months average volume of 0.83 million shares. The company's shares oscillated between $8.60 and $9.13 during the session. Over the last three trading sessions and over the past one month, ImmunoGen Inc.'s shares have lost 5.86% and 24.01%, respectively. Further, the stock has declined 40.90% since the start of this year. The company's stock is trading below its 50-day and 200-day moving averages. ImmunoGen Inc. stock's 200-day moving average of $13.05 is above its 50-day moving average of $11.11. Additionally, the stock has a Relative Strength Index (RSI) of 28.36. Sign up and read the free notes on IMGN at:

www.Investor-Edge.com/IMGN-15Oct2014

On Tuesday, shares in Arrowhead Research Corp. recorded a trading volume of 5.46 million shares, higher than its three months average volume of 4.41 million shares. The stock ended the day at $5.88, which was 2.49% below its previous day's closing of $6.03, and registered an intraday range of $5.50 and $6.17. Arrowhead Research Corp.'s stock has declined 15.03% in the previous three trading sessions, 64.43% in the last one month, and 45.81% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages of $13.83 and $14.49, respectively. Furthermore, shares of Arrowhead Research Corp. have an RSI of 16.57. The complimentary notes on ARWR can be downloaded as in PDF format at:

www.Investor-Edge.com/ARWR-15Oct2014

Chimerix Inc.'s stock plummeted 5.62% to end Tuesday's session at $29.05. The stock recorded a trading volume of 1.06 million shares, above its three months average volume of 0.81 million shares. The company's shares fluctuated between $28.66 and $31.90 during the session. Chimerix Inc.'s shares have lost 8.68% over the previous three trading sessions. However, the stock has surged 40.14% in the last three months and 92.26% since the beginning of 2014. The company's stock is trading above its 50-day and 200-day moving averages. Chimerix Inc. stock's 50-day moving average of $26.71 is above its 200-day moving average of $21.81. Additionally, the stock has an RSI of 58.40. Register for free on Investor-Edge and access the latest research on CMRX at:

www.Investor-Edge.com/CMRX-15Oct2014

On Tuesday, shares in Tekmira Pharmaceuticals Corp. fluctuated between $22.75 and $24.28 before ending the session 0.38% lower at $23.60. The stock reported a trading volume of 2.37 million shares, lower than its three months average volume of 5.10 million shares. Tekmira Pharmaceuticals Corp.'s shares have surged 17.30% in the last one month, 131.83% in the previous three months, and 196.11% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $20.28 and $16.39, respectively. Moreover, shares of Tekmira Pharmaceuticals Corp. have an RSI of 54.19. The complete research on TKMR is available for free at:

www.Investor-Edge.com/TKMR-15Oct2014

Celgene Corp.'s stock finished Tuesday's session 1.14% lower at $86.48. A total of 6.49 million shares were traded, which was above its three months average volume of 4.26 million shares. The stock vacillated between $85.62 and $88.99 during the session. Over the previous three trading sessions and over the last one month, Celgene Corp.'s shares have fallen by 6.39% and 5.51%, respectively. However, from the beginning of 2014, the stock has advanced 2.36%. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $92.01 is greater than its 200-day moving average of $82.42. Celgene Corp.'s stock traded at a PE ratio of 44.44 and has an RSI of 37.72. Free in depth research on CELG is available at:

www.Investor-Edge.com/CELG-15Oct2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED